BioWorld International Correspondent
LONDON u The scientists behind KuDOS Pharmaceuticals Ltd., which was sold to London-based AstraZeneca plc in December 2005 for [pounds sterling]121.5 million (then US$210 million), have left the company to form another start-up, Mission Therapeutics Ltd.
As the latest spinout by the charity Cancer Research UK, Mission has raised [pounds sterling]6 million (US$9.8 million) in its first round to fund the development of small molecules for regulating enzymes in ubiquitin pathways that control cellular response to DNA damage.
Niall Martin, one of the founding scientists, told BioWorld International that while ubiquitin …
No comments:
Post a Comment